SCHEMBL4916136

SCHEMBL4916136

CCOC(=O)c1ccc(NC(=O)Nc2c(F)cc(F)cc2F)cc1

nearest known ligand 0.75

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 8/20 0.75
MEN1 O00255 5/20 0.75
KMT2A Q03164 5/20 0.75
TRPV1 Q8NER1 2/20 0.75
CASP3 P42574 1/20 0.75
SENP7 Q9BQF6 1/20 0.75
GAA P10253 1/20 0.60
ALDH1A1 P00352 1/20 0.59
L3MBTL1 Q9Y468 1/20 0.59
SMN1; SMN2 Q16637 3/20 0.57
NAMPT P43490 2/20 0.57
MAPK1 P28482 3/20 0.56
LMNA P02545 2/20 0.56
USP2 O75604 1/20 0.56
CA12 O43570 1/20 0.55
CA1 P00915 1/20 0.55
CA2 P00918 1/20 0.55
CA9 Q16790 1/20 0.55
NPC1 O15118 5/20 0.54
RAB9A P51151 5/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5175465 0.90 MAPT (0.65) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4122958 0.86 MAPT (1.00) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4913207 0.85 MAPT (0.77) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4117283 0.84 MAPT (0.74) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4112129 0.83 MAPT (0.72) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4110966 0.83 MAPT (0.72) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4118384 0.82 MAPT (0.76) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL11002152 0.81 MAPT (0.66) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4922490 0.81 MAPT (0.76) MAPTMEN1KMT2ATRPV1CASP3
SCHEMBL4113307 0.80 MAPT (0.77) MAPTMEN1KMT2ATRPV1CASP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US claimed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US claimed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LIMITED (GB) 2012-08-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity PROSIDION LTD. (GB) 2008-10-23 US disclosed
EP-1786422-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY Prosidion Limited (GB) 2007-05-23 EP disclosed
WO-2006018662-A2 ARYL UREA DERIVATIVES FOR TREATING OBESITY PROSIDION LIMITED (GB) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080261952-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MAPT 4151/4885MEN1 4843/4885KMT2A 1905/4885
US-20120214808-A1 Aryl Urea Derivatives for Treating Obesity CNR1, GPR119, UTS2R MAPT 4151/4885MEN1 4843/4885KMT2A 1905/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.